SBFM
Sunshine Biopharma Inc.
$2.43
-1.22%
$5.2M
No data for this timeframe.
Vol
Market Cap$5.2M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$18.0K
Inst. Activity1 buys / 2 sells
Reddit Sentiment67° Warm
Recent Activity
Apr 14, 2026
Insider
NATAN DAVID sold 100,000 shares
Director @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
14,634 shares ($18.0K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — EXIT
0 shares ($0.00)
Jun 2, 2026
short_volume
Short Volume: SBFM — 55.2% short (1.0M / 1.8M)
Short: 1,009,574 | Exempt: 204,240 | TRF Vol: 1,828,483 | Short Ratio: 55.2% | Off-exchange volume (
Apr 29, 2026
Event
LANGLARA
Original Approval — INJECTABLE
Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$56.00 (Oct 2025)
Current $2.28
Low $56.00
Median $56.00
High $56.00
1 analysts
$56.00
$56.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2025 | Aegis Capital | REITERATE | Buy → Buy |
| Dec 5, 2024 | Aegis Capital | REITERATE | Buy → Buy |
| Aug 7, 2023 | Aegis Capital | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.20 ▼ -50.0% | $-1.20 — $-1.20 | 69% YoY | 1 |
| Next Q | $-0.20 ▼ -200.0% | $-0.20 — $-0.20 | 89% YoY | 1 |
| Current FY | $-6.30 ▼ -1475.0% | $-6.30 — $-6.30 | 56% YoY | 1 |
| Next FY | $0.20 | $0.20 — $0.20 | 103% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $18.0K | DOUBLED |
| BANK OF AMERICA CORP | $6.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 14, 2026 | NATAN DAVID | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
2 institutional holders with $18.0K total value (14,639 shares) as of 2025-Q4. Top holders: MORGAN, BANK. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 14,634 | $18.0K | 100.0% | DOUBLED +281.7% |
| 2 | BANK OF AMERICA CORP /DE/ | 5 | $6.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 3,834 | 14,634 | +281.7% | $18.0K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 55,700 | 0 | -100.0% | $0.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 21,399 | 0 | -100.0% | $0.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 21,399 | — | $31.9K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 54,093 | — | $77.9K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 19,885 | 206 | -99.0% | $297.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 868 | 19,885 | +2190.9% | $38.0K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 7,640 | 3,834 | -49.8% | $7.3K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 1 | 7,640 | +763900.0% | $22.9K | 2024-Q4 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 14, 2026 | NATAN DAVID | Director | A | 100,000 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Oct 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$56.00 mean target (Oct 2025)
$56.00 Low
$56.00 High
| Metric | Value |
|---|---|
| Current Price | $2.28 |
| Target Low | $56.00 |
| Target Mean | $56.00 |
| Target Median | $56.00 |
| Target High | $56.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.20 | $-1.20 | $-1.20 | 69.2% | -50.0% | 0↑ 1↓ | $0.0B | -8.6% | 1 |
| Next Q 2026-09-30 |
$-0.20 | $-0.20 | $-0.20 | 89.5% | -200.0% | 0↑ 1↓ | $0.0B | -3.4% | 1 |
| Current FY 2026-12-31 |
$-6.30 | $-6.30 | $-6.30 | 56.3% | -1475.0% | 0↑ 1↓ | $0.0B | -2.5% | 1 |
| Next FY 2027-12-31 |
$0.20 | $0.20 | $0.20 | 103.2% | +0.0% | — | $0.0B | 27.2% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.200 | |
| 7d ago | $-1.200 | |
| 30d ago | $-0.800 | -0.400 |
| 60d ago | $0.000 | -1.200 |
| 90d ago | $0.000 | -1.200 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 8, 2025 | Aegis Capital | REITERATE | Buy | Buy |
| Dec 5, 2024 | Aegis Capital | REITERATE | Buy | Buy |
| Aug 7, 2023 | Aegis Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
8 mentions
4 bullish
0 bearish
8 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 18, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 18, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Stock Pulse Weekly Recap — May 18–22, 2026
▲ 1
💬 1
⚡ 0.5
19 MAY 2026 , WHAT ARE THE BIGGEST WINNERS AND WHY ?
▲ 1
💬 1
⚡ 0.5
18 MAY 2026, THE BIGGEST WINNERS TODAY AND WHY ?
▲ 1
💬 0
⚡ 0.5
18 May 2026 , what are the biggest winners and why ?
▲ 1
💬 1
⚡ 0.5
Jun 2, 2026
short_volume
Short Volume: SBFM — 55.2% short (1.0M / 1.8M)
Short: 1,009,574 | Exempt: 204,240 | TRF Vol: 1,828,483 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: SBFM — 64.9% short (1.9M / 2.9M)
Short: 1,880,353 | Exempt: 328,547 | TRF Vol: 2,899,333 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: SBFM — 55.4% short (1.1M / 1.9M)
Short: 1,063,754 | Exempt: 192,938 | TRF Vol: 1,919,205 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: SBFM — 56.1% short (41.5M / 73.9M)
Short: 41,498,469 | Exempt: 6,083,802 | TRF Vol: 73,939,774 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: SBFM — 77.7% short (0.6M / 0.8M)
Short: 589,649 | Exempt: 39,782 | TRF Vol: 758,564 | Short Ratio: 77.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
Clinical Trial
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
Phase Phase 2 — COMPLETED
May 13, 2026
earnings_calendar
SBFM Q1 2026 Earnings Scheduled — 2026-05-13
Apr 29, 2026
FDA
LANGLARA
Original Approval — INJECTABLE
Mar 30, 2026
earnings_calendar
SBFM Q4 2025 Earnings Before Market Open — 2026-03-30